492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancersDavid M. O’Malley, Antonio Jimeno, Amanda Psyrri et al.|Regular and Young Investigator Award Abstracts|2021Cited by 37